Hematologic changes after splenectomy for ovarian cancer debulking surgery, and association with infection and venous thromboembolism.
Adult
Aged
Aged, 80 and over
Cytoreduction Surgical Procedures
Female
Humans
Infections
/ blood
Leukocyte Count
Leukocytosis
/ blood
Middle Aged
Neoplasm Staging
Ovarian Neoplasms
/ pathology
Platelet Count
Postoperative Complications
/ blood
Postoperative Period
Retrospective Studies
Splenectomy
/ adverse effects
Thrombocytosis
/ blood
Time Factors
Venous Thromboembolism
/ blood
Young Adult
ovarian cancer
surgery
surgical procedures, operative
Journal
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
09
03
2020
revised:
10
06
2020
accepted:
12
06
2020
pubmed:
16
7
2020
medline:
10
9
2021
entrez:
16
7
2020
Statut:
ppublish
Résumé
The spleen plays a role in the immune and coagulative responses, yet a splenectomy may be required during ovarian cancer surgery to achieve complete cytoreduction. The aim of the study was to correlate hematologic changes with the development of infection and venous thromboembolism in patients undergoing splenectomy. This single-institution retrospective review includes all patients undergoing splenectomy during cytoreductive surgery for advanced ovarian cancer, March 2001 to December 2016. We compared postoperative hematologic changes (evaluated daily before discharge) in patients developing infection within 30 days' post-surgery (Infection group) with those who did not (No-Infection group). We also compared patients developing venous thromboembolism with those without. A total of 265 patients underwent splenectomy. Median age was 64 years (range 22-88): 146 (55%) patients had stage IIIC and 114 (43%) patients had stage IV. The majority, 201 (76%) patients underwent splenectomy during primary debulking. A total of 132 (50%) patients comprised the Infection group (most common: urinary tract infection, 54%). Median time from surgery to infection was 8 days (range, 0-29). After initial rise in white blood cell count in both groups, the Infection group had a second peak on postoperative day 10 (median 16.6K/mcL, IQR 12.5-21.2) not seen in the No-Infection group (median 12K/mcL, IQR 9.3-16.3). A total of 40 (15%) patients developed venous thromboembolism, median time of 6.5 days (range, 1-43). All patients demonstrated a continuous rise in platelets during postoperative days 0-15. Thrombocytosis was present in 38/40 (95%) patients with venous thromboembolism vs 183/225 (81%) patients without (P=0.036). Median days with thrombocytosis was higher in venous thromboembolism (8 days, range 1-15) vs non groups (6 days, range 1-16, P=0.049). We identified initial leukocytosis after splenectomy in all patients. The Infection group had a second peak in white blood cell count on postoperative day 10, not present in the No-Infection group. Among patients with venous thromboembolism, thrombocytosis was more frequent and of longer duration.
Identifiants
pubmed: 32665236
pii: ijgc-2020-001368
doi: 10.1136/ijgc-2020-001368
pmc: PMC8369877
mid: NIHMS1728375
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1183-1188Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Gynecol Oncol. 2006 Aug;102(2):369-74
pubmed: 16631919
Ann Surg. 2016 May;263(5):961-6
pubmed: 26135691
Surgery. 2015 Sep;158(3):618-26
pubmed: 26209572
Gynecol Oncol. 2006 Feb;100(2):344-8
pubmed: 16202446
J Thromb Haemost. 2010 Jun;8(6):1413-6
pubmed: 20218983
Int J Surg. 2014;12(2):113-9
pubmed: 24316283
J Trauma. 2005 Nov;59(5):1076-80
pubmed: 16385282
Am J Surg. 2010 May;199(5):646-51
pubmed: 20466110
J Clin Oncol. 2003 Dec 15;21(24):4597-603
pubmed: 14673048
Int J Surg. 2015 Dec;24(Pt A):27-32
pubmed: 26493210
Br J Surg. 2015 May;102(6):590-8
pubmed: 25776855
Arch Surg. 2002 Aug;137(8):924-8; discussion 928-9
pubmed: 12146991
Am Surg. 1992 Jul;58(7):387-90
pubmed: 1616181
Am J Surg. 2017 May;213(5):856-861
pubmed: 28433229
Int J Surg. 2015 May;17:10-4
pubmed: 25779211
Surg Infect (Larchmt). 2014 Jun;15(3):221-6
pubmed: 24787382
Int J Gynecol Cancer. 2006 Nov-Dec;16(6):1957-62
pubmed: 17177832
J Gynecol Oncol. 2019 Jan;30(1):e5
pubmed: 30479089